GLP-1

Novo Nordisk has received approval in Singapore for Wegovy as the first treatment for MASH, a liver disease involving fibrosis. It marks a new indication for the weight-loss drug beyond obesity and diabetes. Attention centres on how semaglutide could expand into treating fatty liver disease globally.

Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.

Young people taking GLP-1 receptor agonists, the class of drugs that includes Ozempic and Wegovy, are showing nutritional deficiencies, according to coverage in medical news outlets. The reports add to ongoing scrutiny of the drugs' safety in children and adolescents, with clinicians urged to monitor patients' nutrient intake while on the medications.

Novo Nordisk is lowering the price of its weight-loss drug Wegovy by 20 percent in Sweden, according to multiple Swedish business and news outlets. The move comes as GLP-1 medicines, once marketed primarily as obesity treatments for patients, are increasingly described in industry coverage as lifestyle drugs competing for customers, intensifying pressure on pricing.

Startup accelerator Plug & Play is turning its attention to companion nutrition for people taking GLP-1 weight-loss and diabetes drugs, framing it as the next frontier for the microbiome sector. The idea is that patients on medications like Ozempic, who eat less, may need tailored probiotic and nutrient support to protect gut health and muscle mass while losing weight.

Hershey CEO Kirk Tanner sits down with Fast Company to discuss how the chocolate giant is adapting to consumers using GLP-1 weight-loss drugs, integrating artificial intelligence into its operations, and working to keep a century-old confectionery brand culturally relevant. The interview touches on shifting snacking habits, health trends pressuring candy sales, and how a legacy company balances tradition with technological change.

A randomized, double-blind, placebo-controlled trial published in Nature tested safiglipron, an oral small-molecule GLP-1 receptor agonist, in people with early type 2 diabetes. Unlike injectable GLP-1 drugs such as semaglutide, safiglipron is taken as a pill, which could make treatment easier to access. The publication is drawing attention as drugmakers race to develop oral alternatives to popular injectable weight and diabetes medications.

Drugs in the GLP-1 class, such as Ozempic and Wegovy, are being described as changing more than obesity treatment, with new discussion of their effects on mental health. The Atlantic examines how these medications may influence mood, addiction and behavior, suggesting the story of weight loss medicine is expanding into psychiatry and brain science.

New research indicates that close to one in six children taking GLP-1 weight-loss and diabetes medications develop nutritional deficiencies. The findings raise questions about monitoring and dietary support for young patients on these increasingly prescribed drugs, as clinicians weigh the benefits of treatment against potential long-term nutritional risks in children.

Supplement company Smidge has introduced a GLP-1 companion bundle aimed at supporting digestion and nutrient intake for people taking GLP-1 medications, which are known to affect appetite and gut function. The bundle is positioned as a nutritional support product for users of these weight-loss and diabetes drugs.

A health news roundup covers four topics: cychlorphine, a substance drawing attention for potential effects on testosterone levels; possible links between GLP-1 weight-loss and diabetes drugs and vision loss; and an ongoing salmonella outbreak tied to jalapeño peppers. Together the items touch on medication safety, supplement trends and a foodborne illness investigation that health officials are monitoring.

Some patients taking GLP-1 weight-loss drugs such as Ozempic and Wegovy are experimenting with microdosing, using lower doses than prescribed, often to cut costs or reduce side effects. An obesity medicine doctor is explaining what the practice involves and urging caution, since evidence for smaller-than-approved doses is limited and self-adjusting medication without medical supervision carries risks.

Supplement brand Smidge has introduced a nutrition bundle combining five supplements into a single daily routine, aimed at people taking GLP-1 weight-loss medications. The concept targets nutritional gaps reported by users of drugs like Ozempic and Wegovy, who often eat less and may miss key nutrients. It reflects a broader wave of products being marketed to the fast-growing GLP-1 user base.

A new obesity drug has been described as the most powerful yet after trial participants reportedly lost up to 25% of their body weight. The results, reported by Ars Technica, would surpass figures associated with current GLP-1 medications such as Wegovy and Zepbound, intensifying competition among drugmakers in the fast-growing weight-loss treatment market.

A new wave of obesity medicines is being discussed as the field looks beyond the established GLP-1 drugs semaglutide and tirzepatide. Coverage highlights emerging treatments in development that could expand options for patients and clinicians treating obesity, a category that has drawn enormous attention since GLP-1 therapies reshaped weight-loss care. Details on specific drug candidates remain limited.

Supplement company Smidge has introduced a GLP-1 Companion Bundle aimed at people taking GLP-1 weight-loss medications, combining products intended to support digestive wellness and whole-food nutrition. The announcement was carried on Yahoo Finance. The company positions the bundle as a way to address nutritional gaps and digestive discomfort that can accompany GLP-1 drug use.

A new report finds that 12.4% of teenagers taking GLP-1 weight-loss and diabetes medications are diagnosed with vitamin D deficiency within a year, and few of them receive nutrition counseling to offset the risk. The findings raise concerns about whether young patients on these increasingly prescribed drugs are getting adequate dietary support alongside treatment.